Work

Evaluation of the Efficacy and Safety of FOLFOX in First-Line Treatment of Advanced Pancreatic Cancer

Year: 2025

Type: article

Abstract: Objective: In pancreatic cancer, only 15% to 20% of patients are potentially resectable at diagnosis.Current standard treatment for inoperable and metastatic patients includes: FOLFIRINOX, gemcitabine plus nab-paclitaxel, and NALIRIFOX regimens.Fluorouracil-based treatments can be considered in patient groups with Eastern Cooperative Oncology Group (ECOG) 1-2, advanced age, and multiple comorbidities. Material and Methods:We aimed to evaluate overall survival (OS), progression-free survival (PFS), safety, and laboratory data in patients with unresectable locally advanced and metastatic pancreatic cancer (ECOG performance score 1) who were treated with FOLFOX as first-line therapy.46 patients, who were started on FOLFOX in University of Health Sciences Türkiye, Gülhane Training and Research Hospital between June 1, 2016 and May 1, 2024, were evaluated retrospectively.Results: The median age was 68. 13 patients were locally advanced (28.3%), and 33 patients were in the metastatic stage (71.7%).Partial response was seen in 13 patients (28.2%) and stable response was seen in 19 patients (41.3%) (disease control rate; 69.6%).Median PFS was 5.8 months; median OS was 13.7 months.No patient with locally advanced disease could be operated on during the follow-up.PFS (10 vs. 5 months; p<0.0005) and OS (22 vs. 8 months, p<0.0005) were better for locally advanced disease compared to metastatic disease.Grade 3/4 neutropenia was 21.7%; anemia was 13%, and thrombocytopenia was 13%.Grade 3/4 diarrhea 6.5%. Conclusion:In locally advanced and metastatic pancreatic cancer, the FOLFOX regimen is considered a good alternative treatment protocol in the low performance status, fragile patient group with efficacy and safety data.

Source: Journal of Oncological Sciences

DOI: 10.37047/jos.galenos.2025.2025-3-6